Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Allarity Therapeutics, Inc. (ALLR) has issued an update.
Allarity Therapeutics, Inc. has announced exciting progress in its Phase 2 clinical trial for stenoparib, revealing that several patients with advanced recurrent ovarian cancer have been successfully treated for over 30 weeks. This milestone indicates promising potential for the drug and showcases the company’s commitment to advancing cancer treatment.
For an in-depth examination of ALLR stock, go to TipRanks’ Stock Analysis page.